Colin Broom
Directeur Général chez Pulmotect, Inc.
Fortune : 1 944 $ au 31/07/2023
Postes actifs de Colin Broom
Sociétés | Poste | Début | Fin |
---|---|---|---|
The Royal College of Physicians | Corporate Officer/Principal | - | - |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Directeur/Membre du Conseil | 30/09/2019 | - |
Directeur Général | 30/09/2019 | - | |
Faculty of Pharmaceutical Medicine | Corporate Officer/Principal | - | - |
Historique de carrière de Colin Broom
Anciens postes connus de Colin Broom
Sociétés | Poste | Début | Fin |
---|---|---|---|
NABRIVA THERAPEUTICS PLC | Directeur/Membre du Conseil | 23/06/2017 | 30/07/2023 |
Directeur Général | 12/04/2017 | 24/07/2018 | |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Directeur Général | 28/08/2014 | 23/06/2017 |
NPS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 16/07/2009 | 01/01/2015 |
Independent Dir/Board Member | 09/07/2009 | 01/01/2015 | |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Directeur Technique/Scientifique/R&D | 01/05/2004 | 01/01/2014 |
AMGEN INC. | Corporate Officer/Principal | 01/01/2000 | 01/01/2003 |
Hoechst Marion Roussel, Inc. | Directeur Technique/Scientifique/R&D | 01/01/1999 | 01/01/1999 |
░░░ ░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Colin Broom
University College London | Undergraduate Degree |
St. George's University of London | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Royaume-Uni | 5 |
Autriche | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Director/Board Member | 3 |
Chief Executive Officer | 3 |
Sectorielle
Health Technology | 8 |
Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
AMGEN INC. | Health Technology |
NABRIVA THERAPEUTICS PLC | Health Technology |
Entreprise privées | 7 |
---|---|
NPS Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Faculty of Pharmaceutical Medicine | |
Hoechst Marion Roussel, Inc. | |
The Gi Co., Inc.
The Gi Co., Inc. Pharmaceuticals: OtherHealth Technology The Gi Company Inc. develops drugs to treat gastrointestinal and related diseases. It offers intestinal trefoil factor for the treatment of oral mucositis. The company also has projects in enteritis, proctitis, inflammatory bowel disease, erosive gastro esophageal reflux disease, peptic ulcer disease and gastrointestinal motility disorders, as well as clinical programs in erosive gastritis, ulcerative colitis and corneal wound healing. The company was founded in 1998 and is headquartered in Framingham, MA. | Health Technology |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Health Technology |
- Bourse
- Insiders
- Colin Broom
- Expérience